SCHEDULE: ARK Investment Management Discloses 11.10% Intellia Stake

ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 7 on Schedule 13G, reporting a combined beneficial ownership of 11.10% in Intellia Therapeutics, Inc.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 7 to Schedule 13G regarding their beneficial ownership in Intellia Therapeutics, Inc.
• As of September 30, 2025, the reporting persons collectively beneficially own 11,919,178 shares of Intellia Therapeutics, Inc. Common Stock.
• This aggregate amount represents 11.10% of the class of securities.
• ARK Investment Management LLC holds sole voting power over 11,042,273 shares and sole dispositive power over 11,919,178 shares.
• Catherine D. Wood holds shared voting power over 11,304,561 shares and shared dispositive power over 11,919,178 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Amendment No. 7) and does not contain new operational or financial information about the issuer, thus maintaining a neutral sentiment. The continued significant stake by a prominent investor is a positive signal, but the filing itself is an update rather than a new event.

Positives

• The continued significant beneficial ownership by ARK Investment Management LLC and Catherine D. Wood, totaling 11.10% of Intellia Therapeutics, Inc., may be viewed as a sustained vote of confidence in the company's long-term prospects by a prominent institutional investor.

Future Outlook

NA

Industry Context

Intellia Therapeutics, Inc. operates in the biotechnology sector, focusing on gene editing technologies. ARK Investment Management, led by Catherine D. Wood, is known for its investment strategy centered on disruptive innovation, often including companies in the genomics and biotechnology fields. This filing indicates ARK's continued significant stake in a key player within this innovative sector.

Related Party Transactions

• ARK Innovation ETF, a series of a Delaware statutory trust, is identified as a client of ARK Investment Management LLC that has an interest in the reported securities exceeding 5 percent.

Stakeholder Impact

• Shareholders: Provides transparency regarding the significant ownership stake held by a major institutional investor, which can influence market perception and investor confidence.
• Management: Awareness of a large, active institutional shareholder can influence strategic decisions and corporate governance considerations.

Key Dates

Keywords

Intellia Therapeutics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment Management